ANAHEIM, Calif. — This Cardiology Today video exclusive highlights new research on treatment with apixaban among Department of Defense beneficiaries with nonvalvular atrial fibrillation, compared with other non-vitamin K antagonist oral anticoagulants.
Kiran Gupta, PhD, associate director U.S. CV HEOR, HEOR HO, BMS, highlights data from the ARISTOTLE trial, presented at the American Heart Association Scientific Sessions, that show all-cause medical cost was much lower for apixaban (Eliquis, Bristol-Myers Squibb/Pfizer) vs. warfarin.
“What we continue to do in our scientific journey, data generation and communication plan is to look at pockets of specific populations that physicians would encounter in clinical practice. We’re looking at the elderly, looking at the DOD database and kind of progressing looking at stroke, major bleeding and comparative data between the [non-vitamin K antagonist oral anticoagulants], but it’s also been very exciting looking at cost at the AHA congress,” Poushali Mukerjee, PhD, Executive Director of Global Medical Affairs, BMS, said. “Cost, as we know very well, is a big determinant many times for patients to get the adequate treatment or not.”